Australian biotechnology company Telix Pharmaceuticals Ltd (ASX: TLX) and its China market partner, Grand Pharmaceutical Group Limited (HKG: 0512), have announced the dosing of the first patient in a pivotal Phase III trial for TLX591-CDx (Illucix) in China. TLX591-CDx is a kit for the preparation of Gallium 68 (68Ga) PSMA-11, a radioactive diagnostic agent utilized for the imaging of prostate cancer through positron emission tomography (PET).
Details of the Phase III Illuccix China Study
The Phase III Illuccix China study, registered on ClinicalTrials.gov with the ID NCT05847348, plans to enroll up to 110 patients with biochemically recurrent (BCR) prostate cancer. This open-label, single-arm, multicenter study aims to support the marketing authorization granted to Illuccix by the US FDA, bridging the gap for approval in China.
Prostate Cancer and PET Scanner Market Growth in China
Prostate cancer is an escalating health concern in China, with approximately 110,000 new diagnoses reported last year, increasing at an annual rate of 6%. The use of PET scanners is also on the rise, with projections estimating the number of PET/CT cameras installed in China to reach 1,240 by the end of 2023, a significant increase from the mere 133 installed in 2010.-Fineline Info & Tech
